CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

New England Journal of Medicine
Original article

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica

Phase 3SecukinumabNeutral
AI Analysis

Summary

Phase 3 trial of secukinumab in polymyalgia rheumatica was published in the New England Journal of Medicine. Limited details are available in the provided article abstract.

Clinical Trial Data

Phase

3

Importance:6/10
Sentiment:
0.00
Phase_3Polymyalgia_RheumaticaNEJMSecukinumab
Related Companies

Read the original article

Published by New England Journal of Medicine on June 3, 2026 3:30 AM

Read Original